https://www.scienceopen.com/hosted-document?doi=10.15212/AMM-2025-0012
Announcing a new publication for
Acta Materia Medica journal. The HIV-1 capsid protein (CA) plays a crucial role in viral replication by orchestrating nuclear entry through interactions with host nuclear pore complexes (NPCs). Recent research has revealed that HIV-1 CA actively disrupts NPC architecture via phenylalanine-glycine (FG)-repeat nucleoporin interactions, thereby enabling nuclear translocation of viral components. This mechanistic insight has driven the development of lenacapavir, the first-in-class CA inhibitor approved for multidrug-resistant HIV-1. Lenacapavir competitively blocks CA-NPC binding, stabilizes cytoplasmic capsids, disrupts viral maturation, and demonstrates pan-stage antiviral efficacy and long-acting pharmacokinetics. Clinical trials have indicated its 100% prophylactic efficacy and potential to decrease global HIV incidence. Advances in structural biology, molecular dynamics simulations, and nanotechnology are expected to further inform next-generation therapeutic strategies targeting CA-host interactions. These findings not only redefine HIV-1 treatment paradigms but also have broader implications for combating CA-dependent viruses.
# # # # # #
Acta Materia Medica welcomes the submission of research articles, review articles, databases, mini reviews, commentaries, editorials, short communications, case report articles and study protocols.
Submission Process
Submissions
to Acta Materia Medica are made using ScholarOne, the online submission and peer review system. Registration and access are available at
https://mc04.manuscriptcentral.com/ammed
Queries about the journal can be sent to
editorialoffice@amm-journal.org.
Please visit
https://amm-journal.org/ to learn more about the journal.
Editorial Board: https://amm-journal.org/index.php/editorial-board/
There are no author submission or article processing fees.
Follow
Acta Materia Medica on Twitter
https://twitter.com/AMM_journal;
Facebook (
https://www.facebook.com/AMMjournal)
eISSN 2737-7946
# # # # # #
Mei Wang, Shujing Xu and Haiyong Jia et al. Revolutionizing HIV treatment: unveiling the new frontiers of HIV capsid research.
Acta Materia Medica. 2025. Vol. 4(3):340-343. DOI: 10.15212/AMM-2025-0012